Status: Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Accent TherapeuticsUpdated: Feb 24, 2026Locations: 5
Eligibility criteria
Patients with histologically confirmed solid tumors who have locally recurrent o... [+5]
Clinically unstable central nervous system (CNS) tumors or brain metastasis [+7]